Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Total Current Liabilities: 2017-2025

Historic Total Current Liabilities for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $23.9 million.

  • Dianthus Therapeutics' Total Current Liabilities rose 51.85% to $23.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year increase of 51.85%. This contributed to the annual value of $18.5 million for FY2024, which is 91.59% up from last year.
  • Dianthus Therapeutics' Total Current Liabilities amounted to $23.9 million in Q3 2025, which was up 18.72% from $20.1 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Total Current Liabilities registered a high of $23.9 million during Q3 2025, and its lowest value of $4.0 million during Q2 2023.
  • Moreover, its 3-year median value for Total Current Liabilities was $13.1 million (2023), whereas its average is $13.3 million.
  • Per our database at Business Quant, Dianthus Therapeutics' Total Current Liabilities crashed by 64.16% in 2023 and then skyrocketed by 148.61% in 2024.
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' Total Current Liabilities stood at $8.2 million in 2022, then climbed by 17.09% to $9.6 million in 2023, then skyrocketed by 91.59% to $18.5 million in 2024, then spiked by 51.85% to $23.9 million in 2025.
  • Its Total Current Liabilities stands at $23.9 million for Q3 2025, versus $20.1 million for Q2 2025 and $17.0 million for Q1 2025.